JP6010047B2 - 対流強化送達（ｃｅｄ）による選択的複製性単純ヘルペスウイルスベクターの脳への送達 - Google Patents

対流強化送達（ｃｅｄ）による選択的複製性単純ヘルペスウイルスベクターの脳への送達 Download PDF

Info

Publication number
JP6010047B2
JP6010047B2 JP2013549878A JP2013549878A JP6010047B2 JP 6010047 B2 JP6010047 B2 JP 6010047B2 JP 2013549878 A JP2013549878 A JP 2013549878A JP 2013549878 A JP2013549878 A JP 2013549878A JP 6010047 B2 JP6010047 B2 JP 6010047B2
Authority
JP
Japan
Prior art keywords
vector
injection
albumin
hsv
brain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013549878A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014506563A (ja
JP2014506563A5 (OSRAM
Inventor
ホワイト，エドワード
ストレトフィールド ジル，スティーブン
ストレトフィールド ジル，スティーブン
Original Assignee
レニショー ピーエルシー
レニショー ピーエルシー
レニショー（アイルランド）リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by レニショー ピーエルシー, レニショー ピーエルシー, レニショー（アイルランド）リミテッド filed Critical レニショー ピーエルシー
Publication of JP2014506563A publication Critical patent/JP2014506563A/ja
Publication of JP2014506563A5 publication Critical patent/JP2014506563A5/ja
Application granted granted Critical
Publication of JP6010047B2 publication Critical patent/JP6010047B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16632—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2013549878A 2011-01-22 2012-01-23 対流強化送達（ｃｅｄ）による選択的複製性単純ヘルペスウイルスベクターの脳への送達 Expired - Fee Related JP6010047B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1101167.3A GB201101167D0 (en) 2011-01-22 2011-01-22 Convection enhanced delivery apparatus and method
GB1101167.3 2011-01-22
PCT/GB2012/000062 WO2012098367A1 (en) 2011-01-22 2012-01-23 Delivery of a selectively replicating herpes simplex viral vector to the brain by convection- enhanced delivery (ced)

Publications (3)

Publication Number Publication Date
JP2014506563A JP2014506563A (ja) 2014-03-17
JP2014506563A5 JP2014506563A5 (OSRAM) 2015-01-29
JP6010047B2 true JP6010047B2 (ja) 2016-10-19

Family

ID=43769504

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013549878A Expired - Fee Related JP6010047B2 (ja) 2011-01-22 2012-01-23 対流強化送達（ｃｅｄ）による選択的複製性単純ヘルペスウイルスベクターの脳への送達

Country Status (6)

Country Link
US (1) US8901077B2 (OSRAM)
EP (1) EP2665748A1 (OSRAM)
JP (1) JP6010047B2 (OSRAM)
CN (1) CN103328504A (OSRAM)
GB (1) GB201101167D0 (OSRAM)
WO (1) WO2012098367A1 (OSRAM)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201204263D0 (en) * 2012-03-12 2012-04-25 Renishaw Plc Giloma treatment
GB201308917D0 (en) * 2013-05-17 2013-07-03 Renishaw Plc Delivery
CN114269936A (zh) * 2019-05-31 2022-04-01 阿维塔斯有限公司 向细胞群的病毒传递方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585096A (en) * 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
AU2007244826B2 (en) * 2006-04-25 2013-04-11 The Regents Of The University Of California Administration of growth factors for the treatment of CNS disorders

Also Published As

Publication number Publication date
JP2014506563A (ja) 2014-03-17
WO2012098367A1 (en) 2012-07-26
US20130296246A1 (en) 2013-11-07
EP2665748A1 (en) 2013-11-27
GB201101167D0 (en) 2011-03-09
CN103328504A (zh) 2013-09-25
US8901077B2 (en) 2014-12-02

Similar Documents

Publication Publication Date Title
JP2009535360A (ja) 高分子量神経治療薬の対流増加送達のための組成物および方法
Souweidane et al. Gene therapy for late infantile neuronal ceroid lipofuscinosis: neurosurgical considerations
CN101180397A (zh) 用于癌症治疗基因的肿瘤选择性和高效率表达的新型hTMC启动子和载体
BRPI0710800A2 (pt) administração de fatores de crescimento para o tratamento de distúrbios de snc
JPH10503766A (ja) Ｈｓｖ突然変異体を用いる癌の治療
JP6010047B2 (ja) 対流強化送達（ｃｅｄ）による選択的複製性単純ヘルペスウイルスベクターの脳への送達
Park et al. Distribution of human umbilical cord blood–derived mesenchymal stem cells (hUCB-MSCs) in canines after intracerebroventricular injection
Satoh et al. Posttreatment with adenovirus-mediated gene transfer of calcitonin gene—related peptide to reverse cerebral vasospasm in dogs
Hodgetts et al. Cortical AAV‐CNTF gene therapy combined with intraspinal mesenchymal precursor cell transplantation promotes functional and morphological outcomes after spinal cord injury in adult rats
JP2002529097A (ja) アデノウィルスを介する遺伝子治療
White et al. Evaluation and optimization of the administration of a selectively replicating herpes simplex viral vector to the brain by convection-enhanced delivery
Oh et al. Efficacy of nonviral gene transfer in the canine brain
JPH09505557A (ja) ヒト腫瘍細胞の遺伝子形質転換によるヒト腫瘍の治療
O’Leary et al. Intraparenchymal convection enhanced delivery of AAV in sheep to treat Mucopolysaccharidosis IIIC
KR20250020536A (ko) 타우 단백질 집적 억제용 조성물 및 집적억제 방법
Hampton et al. Method for making selective lesions of the hippocampus in macaque monkeys using NMDA and a longitudinal surgical approach
JP2007532639A (ja) 神経細胞への遺伝子送達方法
CN113260373A (zh) 用于诱导神经可塑性的方法和组合物
US8518391B1 (en) Monocytes as a gene delivery vector for secreted proteins to treat Alzheimer'S disease
White et al. An evaluation of site‐specific immune responses directed against first‐generation adenoviral vectors administered by convection‐enhanced delivery
Hélie-Legoupil et al. In vivo imaging of the barrier properties of the glia limitans during health and neuroinflammation
JP2002532117A (ja) 任意に活性物質をコードする遺伝子が移入された哺乳類細胞の調製物、及びそれらを含有する調製物
US20250161407A1 (en) Medical application and pharmaceutical composition of UbV.E4B protein
Sun et al. Bone Marrow Mesenchymal Stem Cells Transplantation Combined with Exercise Training Synergistically Promoted Functional Recovery After Spinal Cord Injury.
US20230020486A1 (en) Stem Cell Delivery

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141205

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141205

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150814

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150821

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160412

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160711

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160715

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160818

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160915

R150 Certificate of patent or registration of utility model

Ref document number: 6010047

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees